6533b870fe1ef96bd12cfc7e

RESEARCH PRODUCT

Against all odds: anti-IgE for intrinsic asthma?

Marek LommatzschJohann Christian VirchowStephanie KornRoland Buhl

subject

Pulmonary and Respiratory MedicineIntrinsic FactorChest ClinicOmalizumabOmalizumabAsthma PharmacologyImmunoglobulin EAntibodies Monoclonal HumanizedAnti-asthmatic AgentOddsmedicineHumansAnti-Asthmatic Agents1506AsthmaIntrinsic factorbiologybusiness.industrymedicine.diseaseAsthmaImmunity Innaterespiratory tract diseasesAntibodies Anti-IdiotypicClinical trialAsthma MechanismsIntrinsic asthmaImmunologybiology.proteinDisease Progressionbusinessmedicine.drug

description

For many years, pathogenetic concepts and the results of clinical trials supported the view that anti-IgE treatment is specifically effective in allergic asthma. However, there is now growing clinical and mechanistic evidence suggesting that treatment with the anti-IgE antibody omalizumab can be effective in patients with intrinsic asthma. Therefore, large and well-controlled clinical trials with anti-IgE are urgently warranted in patients with intrinsic asthma. In addition, there is a need to find new biomarkers which can identify patients with asthma who respond to anti-IgE treatment.

yearjournalcountryeditionlanguage
2013-05-28Thorax
10.1136/thoraxjnl-2013-203738https://pubmed.ncbi.nlm.nih.gov/23709757